A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to ...
Some results have been hidden because they may be inaccessible to you